Literature DB >> 25039438

Healthcare-associated and nosocomial bacterial infections in cirrhosis: predictors and impact on outcome.

Konstantina Sargenti1, Hanne Prytz, Anna Strand, Emma Nilsson, Evangelos Kalaitzakis.   

Abstract

BACKGROUND & AIMS: Population-based data on the occurrence of healthcare-associated (HCA) and hospital-acquired (HA) bacterial infections in cirrhosis, their predictors, and their impact on outcome are limited.
METHODS: All patients with incident cirrhosis in 2001-2010 residing in an area of 600,000 inhabitants were retrospectively identified. All serious bacterial infections (resulting in or occurring during an inpatient hospital episode) during this period were registered. Acquisition type, site of infection, occurrence of infection-related acute-on-chronic liver failure (ACLF), acute kidney injury (AKI) and bacterial resistance were analysed. Patients were followed longitudinally until death, transplant or end of 2011.
RESULTS: A total of 398 serious infections occurred in 241/633 (38%) patients. Forty-seven per cent were HCA and 21% HA. Proton pump inhibitor (PPI) use was more common in HA (80%) vs. HCA (64%) vs. community-acquired (44%) infections (P < 0.001). In regression analysis, decompensated status, use of antibiotics and PPIs at infection diagnosis were independent predictors of HCA/HA infections (P < 0.05). After adjustment for confounders, HCA/HA infections were significantly related to infection-related ACLF (P < 0.05), but not severe sepsis, AKI or infection-related mortality (P > 0.05). Antibiotic-resistant infections were more frequent among HA (17%) than HCA (6%) or community-acquired (8%) infections (P < 0.05). Antibiotic-resistant HCA/HA infections were independently related to severe sepsis (P < 0.05).
CONCLUSIONS: In a population-based cirrhotic cohort, two-thirds of serious bacterial infections were HCA or HA. Decompensated liver disease, antibiotics and PPIs were predictors of serious HCA/HA infections, which were associated with the development of ACLF. Antibiotic resistance was frequent, especially in HA infections, and contributed to risk of severe sepsis.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute-on-chronic liver failure; bacterial infections; bacterial resistance; cirrhosis; healthcare-associated infection; hospital-acquired infection; outcome; proton pump inhibitors

Mesh:

Substances:

Year:  2014        PMID: 25039438     DOI: 10.1111/liv.12625

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  13 in total

1.  Proton pump inhibitor prescription abuse and sepsis in cirrhosis.

Authors:  Antonio Picardi; Umberto Vespasiani-Gentilucci
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 2.  Liver - guardian, modifier and target of sepsis.

Authors:  Pavel Strnad; Frank Tacke; Alexander Koch; Christian Trautwein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

3.  Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis.

Authors:  Jasmohan S Bajaj; Jacqueline G OʼLeary; Puneeta Tandon; Florence Wong; Guadalupe Garcia-Tsao; Patrick S Kamath; Scott W Biggins; Jennifer C Lai; Hugo E Vargas; Benedict Maliakkal; Michael B Fallon; Paul J Thuluvath; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Am J Gastroenterol       Date:  2019-07       Impact factor: 10.864

Review 4.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

5.  Dysfunction of Circulating Polymorphonuclear Leukocytes and Monocytes in Ambulatory Cirrhotics Predicts Patient Outcome.

Authors:  Konstantina Sargenti; Åsa Johansson; Sara Bertilsson; Inger Mattsby-Baltzer; Daniel Klintman; Evangelos Kalaitzakis
Journal:  Dig Dis Sci       Date:  2016-03-24       Impact factor: 3.199

Review 6.  Bloodstream infections in patients with liver cirrhosis.

Authors:  Michele Bartoletti; Maddalena Giannella; Russell Edward Lewis; Pierluigi Viale
Journal:  Virulence       Date:  2016-02-11       Impact factor: 5.882

Review 7.  Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management.

Authors:  Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  Bacterial load and cytokine profile in patients with cirrhosis following therapy with proton pump inhibitors: a prospective cohort study.

Authors:  Christos Triantos; Maria Kalafateli; Panagiota I Spantidea; Dimitrios Goukos; Efstratios Koutroumpakis; Christos Konstantakis; Stelios F Assimakopoulos; Charalambos Gogos; Athanasia Mouzaki; Georgios Daikos; Konstantinos Thomopoulos
Journal:  Ann Gastroenterol       Date:  2017-04-06

9.  A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients.

Authors:  Cristina Lucidi; Vincenza Di Gregorio; Giancarlo Ceccarelli; Mario Venditti; Oliviero Riggio; Manuela Merli
Journal:  Clinicoecon Outcomes Res       Date:  2017-06-29

10.  Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease.

Authors:  Noam Peleg; Orly Sneh Arbib; Assaf Issachar; Michal Cohen-Naftaly; Marius Braun; Amir Shlomai
Journal:  PLoS One       Date:  2018-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.